the biotech would push forward CRISPR-based drugs for a series of liver and brain diseases, beginning by filing for a first trial in under two years. It was, suffice to say, bold. Arbor had yet ...

The study was led by Feng Zhang, a core institute member at the Broad and an Investigator at the McGovern Institute for Brain Research at MIT. "As CRISPR therapies enter the clinic, there is a ...

and Zhang as the three seminal figures in the development of CRISPR/Cas9 technology: “The attendees are a veritable who’s who of genome editing: Jennifer Doudna of the University of California, ...

"This is a very versatile RNA-guided system with a lot of diverse functionalities," says Feng Zhang ... Previously, Zhang's ...

Critics have harsh words for the Broad Institute’s Eric Lander and Cell over a recent perspective piece describing the history of CRISPR. Furthermore, Jennifer Doudna of the University ... is ...